Lymphoma Clinical Trial
— Epi-RCHOPOfficial title:
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Verified date | March 2023 |
Source | The Lymphoma Academic Research Organisation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21. Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients : DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab
Status | Active, not recruiting |
Enrollment | 214 |
Est. completion date | April 2026 |
Est. primary completion date | January 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | - INCLUSION CRITERIA - for Cohort DLBCL ONLY - 1-Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) with - Phase Ib aaIPI = 2 - Phase II: aaIPI = 1ONLY - 2. Age between 60 and 80 years included - for Cohort FOLLICULAR ONLY - 1-High Tumor Burden (as defined by GELF criteria > 0) frontline follicular lymphoma (FL) with high risk FLIPI 3-5 - 2. Aged between 18 years and 80 years included - 11bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatments (R-CHOP, tazemetostat, Rituximab) - For both Cohorts - 1bis- For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan - 3.ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib) - 4.Signed informed consent - 5.Life expectancy of = 90 days (3 months) before starting tazemetostat - 6.Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula - 7. Adequate bone marrow function as defined as: - ANC = 1500/mm3 (= 1.5 X 109/L) - Platelets = 75,000/mm3 (= 75 X 109/L) without platelet transfusion dependency during the last 7 days - Hemoglobin = 9 g/dL (may receive transfusion) - 8. Adequate liver function as defined as: - Total bilirubin = 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome - Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 X ULN (or = 5 X ULN if related to lymphoma involvement) - Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable. - 9. Left ventricular ejection fraction (LVEF) = 50% of echocardiography or multiple gated acquisition (MUGA) scan - 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation (see appendix 11 - 11. Males with partners of childbearing potential must agree to use reliable forms of contraception during 12 months after last treatment administration - 12. Patient covered by any social security system (for France only) - 13. Patient who understands and speaks one of the country official languages - EXCLUSION CRITERIA - for Cohort DLBCL ___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max) - for Cohort FOLLICULAR ONLY - 14bis. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max) - 17-Pregnant or lactating females - For both Cohorts - 1-Central nervous system or meningeal involvement - 2-Contraindication to any drug contained in the chemotherapy regimen - 3-Prior treatment with tazemetostat or other inhibitor of EZH2 - 4-Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies - 5-Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort) - 6-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit juice and/or grapefruit from diet - 7-Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment) - 8-Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat - 9-Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia - 10-Not applicable - 11-Active uncontrolled infection requiring systemic therapy - 12-Congenital immunodeficiency or known HIV (human immunodeficiency virus infection) - 13-Any other major illness, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study - 14-Patients who have undergone a solid organ transplant - 16-Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy - 18-Person deprived of his/her liberty by a judicial or administrative decision - 19-Adult person under legal protection - 20-Person hospitalized without consent - 21-Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness |
Country | Name | City | State |
---|---|---|---|
Belgium | Institut Jules Bordet | Bruxelles | |
Belgium | CHU de Liege | Liege | |
Belgium | CHRU Mont Godinne | Yvoir | |
France | Centre Hospitalier Victor Dupouy | Argenteuil | |
France | CH d'Avignon - Hôpital Henri Dufaut | Avignon | |
France | CHU de Besançon - Hôpital Jean Minjoz | Besançon | |
France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
France | CH de Chambéry | Chambéry | |
France | CHU d'Estaing | Clermont-Ferrand | |
France | APHP - Hopital Henri Mondor | Creteil | |
France | CHU de Dijon | Dijon | |
France | CHU Grenoble | Grenoble | |
France | CH Départemental de Vendée | La Roche sur Yon | |
France | CHRU Lille - Hôpital Claude Huriez | Lille Cedex | |
France | Chu de Limoges - Hopital Dupuytren | Limoges | |
France | Centre Leon Berard | Lyon | |
France | Institut Paoli Calmette | Marseille | |
France | CHU de Montpellier - Hôpital Saint-Eloi | Montpellier | |
France | CHU de Nantes - Hôtel Dieu | Nantes | |
France | APHP - Hôpital de la Pitié Salpetrière | Paris | |
France | APHP - Hôpital Saint Louis | Paris Cedex 10 | |
France | CH de Perpigan | Perpignan | |
France | CHU Lyon Sud | Pierre-Bénite Cedex | |
France | Chu de Poitiers - Hopital de Miletrie | Poitiers | |
France | CHU de Rennes - Hôpital Pontchaillou | Rennes | |
France | Centre Henri Becquerel | Rouen | |
France | Centre Rene Hugenin | Saint Cloud | |
France | Institut de cancérologie de la Loire | Saint Priest en Jarez | |
France | CHRU de Strasbourg | Strasbourg | |
France | Institut Universitaire du Cancer de Toulouse - Oncopole | Toulouse | |
France | Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
The Lymphoma Academic Research Organisation | Epizyme, Inc. |
Belgium, France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I : Number of Dose Limiting Toxicities | Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D | 1 cycle (1 cycle is 21 days) | |
Primary | Phase I : Number of Dose Limiting Toxicities | Incidence and severity of treatment-emergent AEs qualifying as protocol defined DLT's in cycle 1 and 2 in order to establish the MTD/RP2D | 2 cycles (1 cycle is 21 days) | |
Primary | Phase II - DLBCL Cohort : Complete Response Rate based on local assessment | Complete response rate as determined by Cheson International Work Group (IWG) 2014: Lugano Classification (Deauville scale 1-3) | 8 cycles (1 cycle is 21 days) | |
Primary | Phase II - FL Cohort : Complete Response Rate based on local assessment | Complete response rate as determined by Cheson IWG 2014: Lugano Classification (Deauville scale 1-3) | 8 cycles (1 cycle is 21 days) | |
Secondary | Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat | Change between baseline - 1 month | ||
Secondary | Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP | Change between baseline - 1 month | ||
Secondary | Phase I : Complete response rate (CRR) by central review using Cheson IWG criteria | 8 cycles (1 cycle is 21 days) | ||
Secondary | Phase II - DLBCL Cohort : Number of Adverse Events (AE)/Serious Adverse Events (SAE) | 8 cycles (1 cycle is 21 days) | ||
Secondary | Phase II - DLBCL Cohort : Complete response rate (CRR) by central review using Cheson IWG criteria | 8 cycles (1 cycle is 21 days) | ||
Secondary | Phase II - DLBCL Cohort : Overall response rate (ORR) by central review | 52 weeks | ||
Secondary | Phase II - DLBCL Cohort : Overall response rate (ORR) by central review | 104 weeks | ||
Secondary | Phase II - DLBCL Cohort : progression free survival (PFS) | 52 weeks | ||
Secondary | Phase II - DLBCL Cohort : progression free survival (PFS) | 104 weeks | ||
Secondary | Phase II - DLBCL Cohort : duration of response (DR) | 52 weeks | ||
Secondary | Phase II - DLBCL Cohort : duration of response (DR) | 104 weeks | ||
Secondary | Phase II - DLBCL Cohort : overall survival (OS) | 52 weeks | ||
Secondary | Phase II - DLBCL Cohort : overall survival (OS) | 104 weeks | ||
Secondary | Phase II - DLBCL Cohort : best overall response (BOR) | 104 weeks | ||
Secondary | Phase II - FL cohort : Number of AE/SAE | 8 cycles (1 cycle is 21 days) | ||
Secondary | Phase II - FL cohort : Number of AE/SAE | 13 months | ||
Secondary | Phase II - FL cohort : PET Complete Response Rate (PET-CRR) by central review according to Lugano 2014 criteria | 8 cycles (1 cycle is 21 days) | ||
Secondary | Phase II - FL cohort : Complete Response Rate (CRR) | 31 months | ||
Secondary | Phase II - FL cohort : Overall Response Rate (CRR) | 31 months | ||
Secondary | Phase II - FL cohort : Progression Free Survival (PFS) | 24 months | ||
Secondary | Phase II - FL cohort : Progression Free Survival (PFS) | 31 months | ||
Secondary | Phase II - FL cohort : Event Free Survival (EFS) | 24 months | ||
Secondary | Phase II - FL cohort : Overall Survival (OS) | 24 months | ||
Secondary | Phase II - FL cohort : Duration of Response (DR) | 31 months | ||
Secondary | Phase II - FL cohort : Best Overall Response | 31 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |